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Abstract: The efficacy of cancer treatments is often limited and associated with substantial toxicity.
Appropriate combination of drug targeting specific mechanisms may regulate metabolism of tumor
cells to reduce cancer cell growth and to improve survival. Therefore, we investigated the effects of
anti-diabetic drug Metformin (Met) and a natural compound caffeic acid (trans-3,4-dihydroxycinnamic
acid, CA) alone and in combination to treat an aggressive metastatic human cervical HTB-34 (ATCC
CRL1550) cancer cell line. CA at concentration of 100 µM, unlike Met at 10 mM, activated 5'-adenosine
monophosphate-activated protein kinase (AMPK). What is more, CA contributed to the fueling of
mitochondrial tricarboxylic acids (TCA) cycle with pyruvate by increasing Pyruvate Dehydrogenase
Complex (PDH) activity, while Met promoted glucose catabolism to lactate. Met downregulated
expression of enzymes of fatty acid de novo synthesis, such as ATP Citrate Lyase (ACLY), Fatty Acid
Synthase (FAS), Fatty Acyl-CoA Elongase 6 (ELOVL6), and Stearoyl-CoA Desaturase-1 (SCD1) in
cancer cells. In conclusion, CA mediated reprogramming of glucose processing through TCA cycle
via oxidative decarboxylation. The increased oxidative stress, as a result of CA treatment, sensitized
cancer cells and, acting on cell biosynthesis and bioenergetics, made HTB-34 cells more susceptible
to Met and successfully inhibited neoplastic cells. The combination of Metformin and caffeic acid
to suppress cervical carcinoma cells by two independent mechanisms may provide a promising
approach to cancer treatment.
Keywords: 5′-adenosine monophosphate-activated protein kinase (AMPK); Metformin; caffeic acid;
cervical cancer; metabolic reprogramming
1. Introduction
Despite the recent development of new anti-tumor therapies, cancer still remains one of the leading
causes of death in humans. The malignancy of the cervix is the second most common cancer in women
world-wide [1]. The efficacy of conventional cancer treatment is often limited and associated with
substantial toxicity affecting the whole organism. Moreover, the urgent challenge of therapy is to limit
metastasis of cancer cells in the body. This is extremely difficult due to metabolic advantages developed
by tumors compared with normal tissues. The intensively proliferating cancer cells reprogram their
metabolism to fulfill high metabolic requirements. The critical aspects of metabolic reprogramming in
cancer cells substantially contribute to the Warburg effect, involving changes in the glycolytic pathway.
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Yet, cancer cells were believed not to have functional mitochondria and oxidative phosphorylation
(OXPHOS). The earliest observation of Warburg suggested that cancer cells rely solely on glycolysis
to provide ATP, even in O2 supply [2]. Recent studies present the metabolism of tumor cells as being
much more complex, since most cancer cells have metabolically efficient mitochondria to provide
intermediates (such as citrate for fatty acid (FA) synthesis) and cofactors (NADH, NADPH) for anabolic
pathways [3]. Yet, the inevitable products of mitochondrial oxidative metabolism are Reactive Oxygen
Species (ROS), which play important role in the regulation of numerous cellular events, including
apoptosis. Consequently, ROS have been taken as a target for dietary antioxidant application in
anticancer treatment [4].
It has recently been shown that cancer cells are sensitive to agents that disrupt energy homeostasis,
such as metformin (Met), a dimethylbiguanide used for treatment of diabetes mellitus in humans.
In fact, numerous epidemiological studies confirmed that metformin may significantly decrease the
relative risk of specific cancer incidence and therefore the use of this drug in anticancer therapies has
been considered [5] and even tested in ongoing clinical trials [6]. The precise mechanism by which Met
regulates metabolic pathways in cell is not certain, but it was well established that Met may interfere
with energy metabolism of cancer cells by inhibition of Complex I of the mitochondrial Electron
Transport Chain (ETC), reducing oxygen consumption and decreasing ATP synthesis [3]. Considering
the latter effect, the beneficial impact of Met on tumor incidence in humans was attributed to the
activation of the main energy regulator in cells, 5′-adenosine monophosphate-activated protein kinase
(AMPK). In fact, a protective regulatory function of AMPK was reported against various cancers [7].
Nevertheless, the precise role of AMPK in tumor growth and progression is still unclear, also in
cervical cancers.
Caffeic acid (trans-3,4-dihydroxycinnamic acid, CA) is a potent polyphenolic antioxidant abundant
in coffee, red wine, herbs, berries and fruits—such as apricot, apple, and kiwi—as well as in seeds
and cereals. CA is a major representative of hydroxycinnamic acids and occurs in food mainly as
chlorogenic acid (5-caffeoylquinic acid, an ester of caffeic acid with quinic acid). CA may exert
regulatory effects on ROS signaling in cell and its chemopreventive effects in vitro and in vivo have
been reported before, with several mechanisms of action proposed [8,9]. However, also a pro-survival
effect of CA mediated through a NF-κB signaling pathway was demonstrated in paclitaxel-treated lung
cancer cell lines [10]. The exact role of ROS in CA intracellular action remains unclear and probably
depends on specific conditions. Recent findings indicate that CA may have anticancer effects via
AMPK activation, and such a mechanism was reported in colon cancer cells in vitro [11], but little
is known so far about the action of CA in other tumor cells, especially in the context of neoplastic
cell metabolism.
The distant metabolic implications of AMPK activation in neoplastic cells bring up not only
changes in glucose processing, but also lipid de novo biosynthesis [12]. In eukaryotic cells, tricarboxylic
acid (TCA) cycle generates intermediates for biosyntheses, which are crucial for cell growth, such
as citrate, a substrate for FA de novo synthesis. The increased FA generation is a commonly
observed metabolic alteration during tumorigenesis, providing supply for cell membrane lipids
in rapidly proliferating transformed cells [13]. Based on growing understanding of the role of lipids
in malignancy, it was suggested that effective antitumor strategy may aim to restrain the subsequent
steps involved in formation of long unsaturated FA, molecules that are essential for the function of
cancer cell membranes [12]. Although there is a lack of similarity in molecules, both Met and CA were
reported to restrain FA synthesis within several cancer cell lines and cause tumor cell proliferation
suppression [14,15].
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Along with growing evidence targeting metabolic disturbance of cancer cells, the new strategies to
improve the efficiency of anticancer therapies recognize the energetic and biosynthetic aspects of tumor
cells metabolism. Therefore, the objective of the novel approach is to develop molecularly targeted
anticancer strategies combining specific activities of anticancer compounds in order to improve
the outcome of the treatment [3,16,17]. Recent findings suggest that combined therapy may be
efficient to increase tumor regression, to prolong the remission of cancer, and to prevent metastasis.
In particular, the correct combination of natural compounds having chemopreventive properties and
various cytotoxic drugs regulating specific target proteins or whole metabolic pathways appears very
attractive [18]. Indeed, a wide variety of natural compounds offer the opportunity to address distinct
regulation of metabolism in different types of cancer [19].
In the present paper, we aimed to determine whether Met, CA, and combined treatment of
Met and CA may effectively decrease human cancer cell viability in vitro. To achieve the objectives,
HTB-34 human cervical cancer cells with aggressive metastatic phenotype were employed. We tested
if the combination of Met and CA may enhance cell death in human cervical HTB-34 cancer cell line
compared with compounds acting alone. We explored if the possible mechanism of treatment involves
the activation of apoptosis and/or necrosis. Since the effect of both compounds on AMPK in HTB-34
human cervical cancer cells has not been studied before, we tested how treatment of HTB-34 cells with
CA, Met, or CA/Met implicates the action of AMPK by measuring the phosphorylation of this enzyme
and its protein ACC-1 (involved in FA synthesis) downstream. In the context of targeting metabolic
alterations of cancer cells, it was interesting to explore how Met and CA interfere with metabolism of
tumor cells, especially with glucose processing and TCA cycle supply via oxidative decarboxylation of
pyruvate and also by glutamine funneling to the cycle. As a TCA cycle product, citrate serves as a
precursor for lipid formation. We focused on the effect of Met and CA on the regulatory proteins of
FA de novo biosynthesis. Since the reprogramming of glucose and lipid metabolism in cancer cells is
associated with oxidative stress in mitochondria, we assessed if enhanced ROS production may be
involved in cell death caused by Met and CA action.
2. Results
2.1. Co-Treatment of HTB-34 Cells with Met and CA Potentates Cell Death via Apoptosis, Inhibits Proliferation
of Cells and Induces Changes in Cell Cycle
Met and CA inhibited proliferation of HTB-34 cells, as shown in Figure 1A,B, respectively.
We found that 100 µM treatment of CA for 24 h inhibited proliferation of cells compared with untreated
control (p < 0.05 vs. control). Similarly, the presence of 10 mM Met in culture medium also significantly
deceased viability of cancer cells (p < 0.05 vs. control) and enhanced cytotoxicity (p < 0.05 vs. control)
(Figure 1D). The exposition of HTB-34 cells to CA in the presence of Met caused greater reduction of
cell proliferation compared to CA alone (p < 0.05) and Met alone (p < 0.05, Figure 1C) and aggravated
cell morphology (Figure 1E), observed under phase contrast microscope. Met/CA co-treatment
significantly induced apoptosis compared to necrosis (p < 0.05) (Figure 1F). These changes were
followed by a shift in cell population towards S and G2/M phases of cell cycle after CA and Met/CA
treatment (Figure 1G phase S: p < 0.01 for CA vs. untreated control, p < 0.05 for Met/CA vs. untreated
control; phase G2/M: p < 0.01 for CA vs. untreated control, p < 0.05 for Met/CA vs. untreated control).
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Figure 1. Metformin (Met) and caffeic acid (CA) exert an anti-proliferative effect on HTB-34 human 
cervical cancer cells. Sensitivity of HTB-34 to Met ((A) 100 µM to 100 mM) and CA ((B) 1 µM to 10 
mM) after 24 h treatment as measured with MTT assay. Effect of Met and CA treatment on (C) cell 
proliferation and (D) LDH release; (E) Cell culture morphology under phase contrast light 
microscope after CA (100 µM), Met (10 mM), and Met/CA treatment. The detrimental effect caused 
by Met and CA alone is mainly due to necrosis, while combination of Met and CA significantly 
increase apoptosis in cancer cells (F) followed by a shift towards S and G2/M phases of cell cycle in 
population of treated cells (G). Experiments were repeated three times with similar results. 
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10 mM) after 24 h treatment as measured with MTT assay. Effect of et and treat ent on ( ) cell
proliferation and (D) LDH release; (E) Cell culture morphology under phase contrast light microscope
after CA (100 µM), Met (10 mM), and Met/CA treatment. The detrimental effect caused by Met and
CA alone is mainly due to necrosis, while combination of Met and CA significantly increase apoptosis
in cancer cells (F) followed by a shift towards S and G2/M phases of cell cycle in population of treated
cells (G). Experiments were repeated three times with similar results.
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2.2. CA Activates AMPK, Changes the Activity and Expression of Enzymes Involved in Glucose Catabolism,
Inhibits Glucose Uptake and Lactate Formation in HTB-34 Cells
As shown in Figure 2A, CA activated AMPK in HTB-34 cells, while Met failed to phosphorylate
the enzyme. CA also phosphorylated Acetyl-CoA carboxylase 1 (ACC1) at S79,80. The similar effect
was measured in cells exposed to CA/Met. ATP content was decreased in cells exposed to CA and
Met/CA. CA downregulated glucose transporter GLUT1 expression alone and as co-treatment with
Met (Figure 2B). CA and CA/Met treatment decreased Phosphofructokinase 2 (PFK2) activity by its
dephosphorylation on S466 residue. To examine the effect of Met and CA on the process of oxidative
decarboxylation, the phosphorylation (deactivation) of Pyruvate Dehydrogenase Complex (PDH) at
S293 by the action of Pyruvate Dehydrogenase Kinase (PDK) was assessed. The activation of PDH
caused by CA was followed by significant decrease in PDK activity (p < 0.05 vs. untreated control).
Met inhibited PDH activity and caused significant rise in PDK activity (p < 0.01 vs. untreated control).
CA, when co-treated with Met, antagonized its effect on PDH phosphorylation and PDK activity.
Any changes in expression of glutaminase (GLS) were not observed (Figure 2B).
The exposition of HTB-34 cells to CA significantly inhibited glucose consumption (Figure 2C,
p < 0.001 vs. Met, p < 0.001 vs. CA/Met) and substantially decreased the lactate level in medium when
compared to the effect of Met (Figure 2C, p < 0.001 vs. Met, p < 0.001 vs. CA/Met). The co-treatment of
HTB-34 cells with Met and CA significantly limited lactate excretion compared with Met-treated cells
(p < 0.05 vs. Met).
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Figure 2. CA activates AMPK in HTB-34 cells along with increasing pyruvate decarboxylation via 
PDH complex and decreasing glucose consumption and lactate production. Immunoblot analysis 
(the details described in Materials and Methods) reveals enhanced phosphorylation of AMPK on T172 
residue by CA alone and Met/CA co-treatment along with activation of AMPK downstream ACC-1 
and decrease of ATP content (A); Met and CA have slight, opposite effect on glucose uptake via 
GLUT-1. CA and Met/CA cause loss of PFK-2 activity. CA increases PDH-E1α phosphorylation on S293 
and inhibits PDH kinase (PDK) activity facilitating pyruvate flux via PDH complex. Note the opposing 
effect of Met on PDH phosphorylation (caused by PDK activation) compared with CA and recovery 
of metformin-inhibited PDH complex by co-treatment with CA. CA, Met, and Met/CA treatment has 
no effect on Glutaminase (GLS) expression (B); For Western blot analyses β-actin was used as the 
protein loading control, band intensities were quantified by densitometry analysis and expressed 
relative to the control (* p < 0.05 vs. untreated control). CA decreases glucose consumption and lactate 
release into culture medium (C) after 24 h of incubation and attenuates the effect of Met. CA was used 
at 100 µM and Met at 10 mM for 24 h. Experiments were repeated three times with similar results. 
2.3. CA Augments Mitochondrial Oxidative Stress 
In present experiments mitochondrial superoxide formation was measured by MitoSox staining 
followed by cytometry analysis. As shown in Figure 3A, CA was a most potent ROS inducer and the 
effect was preserved after co-treatment with Met, while Met itself caused no effect (p < 0.05 for CA 
vs. Met, p < 0.05 for CA vs. CA/Met), as also shown on microphotographs (Figure 3B). 
 
Figure 3. CA and Met/CA causes significantly enhanced generation of mitochondrial ROS measured 
with MitoSox Red probe by flow cytometry (A) and visualized by fluorescence microscopy after 
incubation of HTB-34 cells with Met at 10 mM and CA at 100 µM for 24 h; (B) note the induction of 
mitochondrial oxidative stress after incubation of cells with CA and Met/CA (red fluorescence 
indicate mitochondrial superoxide). Experiments were repeated three times with similar results. 
Figure 2. CA activates AMPK in HTB-34 cells along with increasing pyruvate decarboxylation via
PDH complex and decreasing glucose consumption and lactate production. Immunoblot analysis
(the details described in Materials and Methods) reveals enhanced phosphorylation of AMPK on T172
residue by CA alone and Met/CA co-treatment along with activation of AMPK downstream ACC-1
and decrease of ATP content (A); Met and CA have slight, opposite effect on glucose uptake via GLUT-1.
CA and Met/CA cause loss of PFK-2 activity. CA increases PDH-E1α phosphorylation on S293 and
inhibits PDH kinase (PDK) activity facilitating pyruvate flux via PDH complex. Note the opposing
effect of Met on PDH phosphorylation (caused by PDK activation) compared with CA and recovery of
metformin-inhibited PDH complex by co-treatment with CA. CA, Met, and Met/CA treatment has no
effect on Glutaminase (GLS) expression (B); For Western blot analyses β-actin was used as the protein
loading control, band intensities were quantified by densitometry analysis and expressed relative to
the control (* p < 0.05 vs. untreated control). CA decreases glucose consumption and lactate release into
culture medium (C) after 24 h of incubation and attenuates the effect of Met. CA was used at 100 µM
and Met at 10 mM for 24 h. Experiments were repeated three times with similar results.
2.3. CA Augments Mitochondrial Oxidative Stress
In present experiments mitochondrial superoxide formation was measured by MitoSox staining
followed by cytometry analysis. As shown in Figure 3A, CA was a most potent ROS inducer and the
effect was preserved after co-treatment with Met, while Met itself caused no effect (p < 0.05 for CA vs.
Met, p < 0.05 for CA vs. CA/Met), as also shown on microphotographs (Figure 3B).
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2.4. Met Treatment Attenuates Fatty Acids (FA) De Novo Synthesis by Decreasing of Expression of
Regulatory Enzymes
During energy depletion, AMPK inhibits FA synthesis not only by direct phosphorylation and
inactivation of ACC1, but also by exerting the effect on regulatory enzymes of the pathway at the
level of gene expression [11,12]. Therefore, we investigated whether Met and CA may decrease FA de
novo synthesis by downregulation of enzymes: ATP Citrate Lyase (ACLY), Fatty Acid Synthase (FAS),
Stearoyl-CoA Desaturase-1 (SCD1), and Fatty Acyl-CoA Elongase 6 (ELOVL6). Met caused a decrease
in protein amounts of all enzymes, as shown in Figure 4A. The quantitation of total unsaturated lipids
in HTB-34 cells exposed to compounds revealed the same pattern, since Met alone and as co-treatment
with CA significantly decreased the amount of FA (p < 0.05 for Met vs. untreated control, p < 0.01 for
Met/CA vs. untreated control) (Figure 4B).
Int. J. Mol. Sci. 2017, 18, 462 7 of 15 
2.4. Met Treatment Attenuates Fatty Acids (FA) De Novo Synthesis by Decreasing of Expression of 
Regulatory Enzymes 
During energy depletion, AMPK inhibits FA synthesis not only by direct phosphorylation and 
inactivation of ACC1, but also by exerting the effect on regulatory enzymes of the pathway at the 
level of gene expression [11,12]. Therefore, we investigated whether et and CA ay decrease FA 
de novo synthesis by downregulation of enzymes: ATP Citrate Lyase (ACLY), Fatty Acid Synthase 
(FAS), Stearoyl-CoA Desaturase-1 (SCD1), and Fatty Acyl-CoA Elongase 6 (ELOVL6). Met caused a 
decrease in protein amounts of all enzymes, as shown in Figure 4A. The quantitation of total 
unsaturated lipids in HTB-34 cells exposed to compounds revealed the same pattern, since Met 
alone and as co-treatment with CA significantly decreased the amount of FA (p < 0.05 for Met vs. 
untreated control, p < 0.01 for Met/CA vs. untreated control) (Figure 4B). 
 
(A) (B) 
Figure 4. Met decreases expression of lipogenic genes (A) and unsaturated FA content (B) in human 
cervical carcinoma HTB-34 cells. Total cell lysates were subjected to SDS-PAGE followed by Western 
blot analysis and chemiluminescent detection (band intensities were quantified by densitometry 
analysis; the details described in Material and Methods, * p < 0.05 vs. untreated control). Note that 
co-treatment of cells with Met and CA for 24 h restrains the expression of ACLY, FASN, ELOVL6, 
and SCD1 (A) and significantly decreases unsaturated FA content in cancer cells, as measured by 
spectrophotometric assay. Data shown here are from a representative experiment repeated three 
times with similar results and presented as mean values ± SD (B). 
3. Discussion 
Since metabolic reprogramming of tumors may cause a selective advantage for survival of 
transformed cells, the recognition of the role of master regulatory enzymes in the metabolic network 
is of particular interest. It has recently been suggested that the regulation of AMPK by biguanides 
and by naturally occurring compounds may provide potential therapeutic benefits [5]. Extending 
these findings, we aimed to assess if the intervention in lipid biosynthesis and the regulation of 
metabolic pathways within neoplastic cells via AMPK and TCA cycle supply may be a potent 
strategy for improving cancer treatment efficacy [20]. Despite extensive ongoing research, the 
function of key metabolic regulators in cancer has only been partially understood. To analyze the 
action of Met and CA in cervical tumor, human HTB-34 cancer cells were used. Recently both 
compounds, CA and Met, were independently reported to activate AMPK and to exert anti-cancer 
effect via AMPK-dependent mechanisms in other cancer cell lines in vitro [14,15]. 
In most cancer cells, increased glucose uptake and enhanced glycolysis to lactate provides 
energy and contributes to the rapid growth and cellular division typical for cancer cells. In the 
present study, CA alone and applied with Met reduces the expression of tumor cell glucose 
transporter, GLUT1. Cancer cells very effectively supply glucose even at its low concentration in 
bloodstream, as Km value of GLUT1 transporter is about 1 mM. Natarelli et al. reported that CA has 
no effect on GLUT1 expression and membrane localization in normal endothelial cells, which might 
Figure 4. Met decreases expression of lipogenic genes (A) and unsaturated FA content (B) in human
cervical carcinoma HTB-34 cells. Total cell lysates were subjected to SDS-PAGE followed by Western blot
analysis and chemiluminescent detection (band intensities were quantified by densitometry analysis;
the details described in Material and Methods, * p < 0.05 vs. untreated control). Note that co-treatment
of cells with Met and CA for 24 h restrains the expression of ACLY, FASN, ELOVL6, and SCD1 (A)
and significantly decreases unsaturated FA content in cancer cells, as measured by spectrophotometric
assay. Data shown here are from a representative experiment repeated three times with similar results
and presented as mean values ± SD (B).
3. Discussion
Since metabolic reprogramming of tumors may cause a selective advantage for survival of
transformed cells, the recognition of the role of master regulatory enzymes in the metabolic network is
of particular interest. It has recently been suggested that the regulation of AMPK by biguanides and
by naturally occurring compounds may provide potential therapeutic benefits [5]. Extending these
findings, we aimed to assess if the intervention in lipid biosynthesis and the regulation of metabolic
pathways within neoplastic cells via AMPK and TCA cycle supply may be a potent strategy for
improving cancer treatment efficacy [20]. Despite extensive ongoing research, the function of key
metabolic regulators in cancer has only been partially understood. To analyze the action of Met and
CA in cervical tumor, human HTB-34 cancer cells were used. Recently both compounds, CA and Met,
were independently reported to activate AMPK and to exert anti-cancer effect via AMPK-dependent
mechanisms in other cancer cell lines in vitro [14,15].
In most cancer cells, increased glucose uptake and enhanced glycolysis to lactate provides energy
and contributes to the rapid growth and cellular division typical for cancer cells. In the present study,
CA alone and applied with Met reduces the expression of tumor cell glucose transporter, GLUT1.
Cancer cells very effectively supply glucose even at its low concentration in bloodstream, as Km
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value of GLUT1 transporter is about 1 mM. Natarelli et al. reported that CA has no effect on GLUT1
expression and membrane localization in normal endothelial cells, which might suggest selective effect
of CA in neoplastic cells, but more extensive study is necessary [21]. CA, also unlike Met, reduces the
activity of PFK2, an enzyme regulating the rate of glycolysis. The decrease of PFK2 activity, together
with GLUT1 downregulation caused by CA, probably slows down the rate of glycolysis in HTB-34
cells. The effect is preserved after Met/CA treatment, revealing opposite metabolic action of both
tested compounds, CA and Met. The aggravation of glucose catabolism is reflected in the reduced
amount of lactate produced by cells due to the exposure to CA. The boosted lactate production was
reported as primary metabolic change caused by Met in tumor cells [15], which is also confirmed by our
observations. On the other hand, Met exerted antitumorigenic effect in cervical carcinoma HeLa and
SiHa cells by decreasing the expression of a limiting glycolytic enzyme Pyruvate kinase muscle isozyme
M2 (PKM2) involved in mTOR-dependent pathway regulating epithelial-mesenchymal transition
(EMT), as reported by Cheng et al. [22].
Along with vigorously promoted transformation of pyruvate to lactate in cancer cells, TCA cycle
metabolites are strongly decreased [23]. In our study, CA—unlike Met—substantially contributes
to fueling the TCA cycle with pyruvate. The enhanced intermediate entry to TCA cycle occurs
due to increased PDH activity. Mitochondrial PDH complex catalyzes the irreversible oxidative
decarboxylation of pyruvate to acetylCo-A. PDH is a key regulatory point of metabolic pathways,
which are determinant for the overall glucose and lipid disposal within the cell. The activity state
of PDH is precisely regulated by the covalent modification via specific kinase (PDK), which in turn
was reported as a subject to anticancer intervention [20,24]. In present experiments, CA inhibits
PDK activity in HTB-34 cells and the effect is opposite to that of Met. What is more, when cells
are exposed concomitantly to both compounds, CA attenuates the action of Met by stimulating
oxidative decarboxylation via PDH/PDK. Previously, the phenethyl ester of caffeic acid (CAPE) was
reported to modulate PDK1 at the level of its gene expression in a context of induction of hypoxia via
hypoxia-inducible factor 1α (HIF1α), which might have influenced cancer cell adaptation to metabolic
demands [25].
The facilitated glutamine catabolism is an additional important source for energy production in
tumor cells, besides glucose. While carbon flux via oxidative decarboxylation from pyruvate is limited,
glutamine provides carbons to feed the TCA cycle, and GLS serves as a key regulator of this substrate
entry to TCA [26]. Such metabolic adaptation of neoplastic cells may be problematic, because even
when glucose supply is decreased, glutamine may rebalance the metabolism and provide a carbon
flux for biosynthesis. Here, we did not observe any changes in GLS expression due to CA or/and Met
treatment. The TCA cycle has not been additionally supplied with metabolic intermediates via GLS.
Our data are consistent with findings of Janzer et al. [23] that glutamine uptake is not changed by
biguanides action in cancer cells.
The enhanced FA synthesis provides lipids for membrane biogenesis and promotes the growth
and survival of neoplastic cell, playing a key role in the metabolic phenotype of tumor cells [13].
Our data show that CA co-treatment with Met activates AMPK and suppresses its downstream
enzyme, ACC1, involved in lipid biosynthesis. Therefore, it was of interest to find out if tested
compounds may interfere with lipid content within the cells. We measured that Met and CA decrease
the total amount of unsaturated FA in cancer cells. To explore the mechanism of that observation, we
focused on the expression of subsequent regulatory enzymes involved in FA synthesis (ACLY, FAS),
elongation (ELOVL6) and desaturation of FA (SCD1). In tumors, the overexpression of those regulatory
enzymes was linked to the fact that neoplastic cells tend to be invasive and metastatic [12]. In our
experiments, the greatest downregulation of ACLY, FAS, ELOVL6, and SCD1 proteins expression
was measured after treatment of cells with Met and Met/CA suggesting that major effect on FA
synthesis impairment is exerted by Met. Indeed, Met was reported before to alleviate intracellular FA
synthesis [11] and that metabolic alteration was attributed to inhibition of mitochondrial respiration
caused by the drug [10]. It may also be observed that the impaired FA biosynthesis in HTB-34 cells is
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a consequence of restrained funneling of the TCA cycle via PDH complex and subsequent reduced
formation of substrate for FA de novo synthesis caused by Met (Figure 5).Int. J. Mol. Sci. 2017, 18, 462 9 of 15 
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Figure 5. The effects of Met (green path), CA (yellow path), and Met/CA co-treatment (purple path)
on oxidative metabolism and fatty acids biosynthesis in HTB-34 cells. Met promotes glycolysis to
lactate and regulates FA de novo synthesis. CA activates AMPK, enhances oxidative metabolism of
glucose via PDH and ROS formation in mitochondria and apoptosis. Met/CA activates AMPK, inhibits
FA biosynthesis in the short-term via ACC1 and in the long-term by downregulation of ACLY, FAS,
ELOVL6, and SCD1 enzymes expression.
The mechanism of suppression of tumor cells growth due to impaired lipogenesis, involving
activation of AMPK and blocking of its downstream protein ACC1, was reported before and such
activity of Met was studied in several cancer cell lines [7,27]. Griss et al. showed that Met reduced
production of metabolic intermediates of TCA cycle and suppressed FA de novo synthesis, which
resulted in decreased proliferation of non-small cell lung cancer H1299 cells [28]. Chiang et al. reported
that augmentation of AMPK cascade and subsequent inhibition of FAS expression caused by exposition
of colon cancer CRC cells to CA derivatives inhibited the growth of cells [14]. The results presented by
Hwang et al. indicated that Chlorogenic Acid derivatives isolated from Salicornia herbacea may exert
cytotoxic effect on and decrease proliferation of human Hep G2 cells, including AMPK activation and
resulting impaired expression of SREBP-1c and FAS proteins [29]. A similar mechanism was reported
in Hep G2 cells for other polyphenolic compound, Epigallocatechin Gallate (EGCG) [30]. Taking into
consideration the anti-proliferative activity of CA and Met involving impaired lipid metabolism,
we can speculate that the alleviation of FA biosynthesis due to Met action and the restoration of
PDH caused by CA may result in the impairment of proliferation and survival of cervical carcinoma
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HTB-34 cells. What is more, the regulation of metabolic events combined with modulation of the
cell cycle by Met was suggested to suppress the growth of several neoplastic cell lines [28]. Cai et al.
reported that Met at a concentration of 10 mM inhibited proliferation and induced G0/G1 phase
arrest in human esophageal squamous cell carcinomas [31]. Also, our study revealed that exposition
of HTB-34 cells to Met increased the population of cells in G0/G1 phase. CA at a concentration
of 80 µM was recently reported by Murad et al. to decrease cell viability by stimulating apoptosis
in human colon adenocarcinoma HT-29 cell culture and by promoting specific changes in cell cycle
regulation [8]. Kuo et al. showed that cell proliferation of TW2.6 human oral squamous carcinoma cells
was suppressed by caffeic acid phenethyl ester through a decrease in G1 phase cell population with
concomitant increase in G2/M phase and enhanced apoptosis, which was consistent with our findings
considering cells exposed to CA and CA/Met. Kuo et al. attributed the effect to the attenuation of
G2/M checkpoint, essential for DNA damage repair [32]. It may be presumed that enhanced ROS,
produced within cells due to exposition to CA, may promote DNA damage instead of restoration and
cumulating effect of aberrations may lead to cell death. ROS are vigorously produced by mitochondrial
ETC as a consequence of oxidative metabolism and active TCA cycle. It was well established that
in cancer cells the excessive amounts of ROS may accumulate and trigger death program (Figure 5).
Recently, it was found that AMPK activation may be linked to ROS production [33,34]. It was also
suggested that anticancer activity of CA is due to its ability to regulate ROS-induced cell death, but
the mechanism is complex and depend on cellular context [7,8]. However, our data show significant
connection of pyruvate funneling into TCA cycle and enhanced ROS formation after treatment of
HTB-34 cells with CA. Further experiments would help to elucidate the involvement of ROS into
mechanism of CA action in HTB-34 cells.
In our study, concerted action of both compounds, CA and Met, exerts an anti-proliferative effect
on cervical carcinoma HTB-34 cells, followed by the decrease in the number of cells. Co-treatment of
cells with Met and CA results in apoptosis as a supreme way of cell death and the effect is greater
than that of CA and Met applied alone. At the same time, the inhibition of cell growth caused by
Met is mainly due to necrosis. On the basis of the results obtained, one cannot unambiguously
elucidate why apoptosis increases in HTB-34 cells exposed to Met/CA. However, our data suggest that
the employment of both compounds to suppress cervical carcinoma cells may provide a promising
approach for cancer treatment. On the other hand, the main problem with natural dietary products
is that effective, usually micromolar, concentrations of bioactive compounds are rather transient in
humans. Plasma concentration of CA has been reported rarely to exceed 1 µM after the consumption
of 10–100 mg of a single compound in humans [35], while Met occurs at 10 mM in human plasma
and that level may be sustained much longer [9,15,36]. Therefore, in our study we focused on cervical
cancer as an experimental model, since the location of tumor within the body might provide the
opportunity to use the bioactive compound as a topical formulation, bypassing the problem of low
CA bioavailability in bloodstream. The studies on cellular uptake of CA by cancer cells report that
phenolic acids are absorbed and metabolized by cancer cells [11]. Accumulating evidence addresses
the application of AMPK activators, such as Met and CA, in medical treatment of several metabolic
disorders including cancer [8]. Moreover, the emerging data highlight mitochondrial metabolism as
essential for tumorigenesis. Consequently, the combination of two or more compounds, regarding
different mechanisms of action on metabolic pathways and low toxicity in humans, is of interest.
In our experiments, we aimed to study the influence of compounds on metabolic reprogramming
of late-stage invasive cervical carcinoma cells. Therefore, the aggressive metastatic HTB-34 line with
epithelial morphology has been selected due to advanced malignant transformation of the cells.
HTB-34 cells were obtained from secondary cervical tumor and they had undergone epithelial to
mesenchymal transition (EMT) and subsequent mesenchymal to epithelial transition (MET). The data
obtained from only one particular cancer cell line must be interpreted with caution, since the regulation
of biochemical pathways in various cervical carcinoma cell lines may differ remarkably depending on
stage of tumor and epithelial/mesenchymal characteristics.
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We conclude that, in cervical carcinoma HTB-34 cells, CA modestly activates AMPK, while Met
exerts its effect on FA biosynthesis by downregulation of several enzymes involved in the de novo
synthesis of long unsaturated FA, such as ACLY, FAS, ELOVL6, and SCD1. The alleviation of FA
synthesis caused by Met due to a reduction in citrate for fueling of FA biosynthesis probably plays a
significant role in the restraining of the proliferation rate and promoting cell death in cervical cancer
cells exposed to Met. CA mediates the metabolic reprogramming of HTB-34 cell by enhancing of
glucose processing via oxidative decarboxylation. The increased oxidative stress, as a result of CA
treatment, sensitizes cancer cells and make HTB-34 cells more susceptible to Met. Our data suggest
that CA and Met induce cell death in human cervical metastatic cells by two independent mechanisms,
CA by increasing ROS production and Met by suppressing of substrate formation for FA biosynthesis.
The treatment of neoplastic cells with both compounds provides a promising approach to evoke
metastatic cervical HTB-34 cells death.
4. Materials and Methods
4.1. Cell Culture and Incubation Conditions
Human cell line HTB-34 (ATCC designation MS751) was derived from the American Type Cell
Culture collection. Cells were maintained as a monolayer culture in EMEM-Eagle’s Minimum Essential
Medium (Lonza, Walkersville, MD, USA), supplemented with 10% v/v FBS (Eurex Sp z o.o., Gdansk,
Poland) and 50 µg/mL of gentamicin, at 37 ◦C in a humidified atmosphere of 5% CO2 and passaged
twice a week. For experiments, HTB-34 cells at a density of 1.5 × 105 cells/mL were placed in cell
culture plates (Sarstedt, Numbrecht, Germany) and incubated to reach adequate confluency. Then cells
were washed with PBS solution (Lonza) and kept for 24 h in EMEM-containing antibiotic and 0.5% v/v
of bovine serum albumin (BSA, Sigma-Aldrich, Seelze, Germany). This step was taken in attempt to
silence cells, since the amount of insulin in serum-containing medium may be higher compared with
cells in vivo. Then the medium was replaced with a new EMEM/0.5% BSA with adequate volumes of
stock solution of CA (100 µM/L, Sigma-Aldrich) or Met (10 mM, Sigma-Aldrich) or CA (100 µM) and
Met (10 mM) and exposition of cells to appropriate compound was continued for 24 h. The 1% (v/v)
of CA solvent, dimethyl sulfoxide (DMSO) was added to an untreated control and to Met containing
wells. After incubation, cells and media were collected.
The number of cells was assessed by automatic cell counter Countess (Gibco Laboratories,
Gaithersburg, MD, USA). The morphology of cell culture was investigated by an inverted
light microscope (Olympus IX-70 microscope with fluorescence, Olympus, Hamburg, Germany).
Representative images were obtained at 20×magnification.
4.2. Anti-Proliferative Assay
MTT, 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyl tetrazolium bromide was purchased from
Sigma-Aldrich, Seelze, Germany. Briefly, 200 µL of a suspension of exponentially dividing cells
was placed in each well of a 96-well microtiter plate (Sarstedt, Numbrecht, Germany) in medium.
Untreated cells were cultured in medium and solvent (positive control, 100% of growth). The test
was conducted as described previously [37]. The absorbance was measured at 570 nm (the reference
wavelength was 630 nm) using a microplate reader Infinite M200 Pro (Tecan, Salzburg, Austria).
4.3. Cytotoxicity Assay
The cytotoxicity was measured as Lactate Dehydrogenase (LDH) leakage from cells exposed to
compounds and determined by using commercially available BIOLABO SAS–L.D.H. (LDH-P) SFBC
Modified Method kit according to manufacture protocol (Biolabo S.A., Maizy, France). For LDH test,
cells were seeded into a 96-well plate and exposed to drugs as described in 4.1. Afterwards, 24 h of
incubation media were collected and cells were lysed (Triton-X, 1% v/v, Sigma-Aldrich) to release the
intracellular LDH. Then NADH concentration generated in the reaction of the reduction of pyruvate
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was measured at 340 nm using microplate reader (Tecan). For each sample the result was given as the
percentage of LDH in the medium versus total LDH activity in the cells.
4.4. Cell Apoptosis and Necrosis Quantitation
After incubation cells were collected and analyzed on FACSCanto10C flow cytometer, using BD
System Software (BD FACSDIVA V8.0.1, BD Biosciences Immunocytometry Systems, San Jose, CA,
USA). Fluorescent dyes Annexin-V (excitation/emission 490/515 nm) and Ethidium homodimer
(EthD-III, excitation/emission 528/617 nm) were used (Biotium, Fremont, CA, USA). The cells
were gated according to forward (FSC), side scatter (SSC), and appropriate fluorescence parameters.
The living cells were defined as negative for Anexin-V and EthD-III, the apoptotic cells consisted
of Anexin-V positive/EthD-III negative cells (early apoptosis) and Anexin-V/EthD-III positive cells
(late apoptosis); the necrotic cells were Anexin-V negative and EthD-III. The results were given as the
percentage of apoptotic or necrotic cells of the total counted cells (Figure S1).
4.5. Cell Cycle Analysis
For detection of cell cycle distribution upon different treatments, cells were trypsinized, washed
with PBS, and centrifuged for 5 min at 250× g. BD IntraSure kit (BD Biosciences) was used for cell
fixation and permeabilization, according to manufacturer’s protocol and followed by 15 min of dark
incubation in room temperature of cells with Ki-67 antibody (Thermo Fisher Scientific Inc., Waltham,
MA, USA). Thereafter, cells were stained with DAPI fluorescent dye (excitation maximum at 360 nm
and fluorescence emission maximum at 460 nm, Thermo Fisher Scientific Inc.) and processed for
FACS-based cell cycle analysis (Figure S2).
4.6. Immunoblot Analysis
Cells for immunoblot analysis were homogenized in M-PER buffer (Thermo Fisher Scientific Inc.)
with a protease inhibitor cocktail (Merck, Darmstadt, Germany). The protein samples were resolved
via standard SDS-PAGE and then transferred to PVDF membranes. The membranes were blocked with
buffer contained 1% BSA in TBST (20 mM of Tris-hydrochloride, pH 7.5, 150 mM NaCl, 0.05% Tween 20;
BioRad, Laboratories, Hercules CA, USA) as described previously [38]. Immunoblottings were
performed using primary antibodies: anti-AMPK, (Cell signaling, Danvers, MA, USA), anti-p-AMPK
(Cell signaling), anti-p-PDH (Abcam, Cambridge, MA, USA), anti-PDH (Cell signaling) anti-GLUT1
(Santa Cruz Biotech., Santa Cruz, CA, USA), anti-PFK2 (Santa Cruz Biotech), anti-p-ACC1
(Cell signaling), anti-ACC1 (Cell signaling), anti-ACLY, anti-FAS (Santa Cruz Biotech), anti-ELOVL6
(Santa Cruz Biotech), and anti-SCD1 (Santa Cruz Biotech), followed by HRP-linked secondary
antibody (Santa Cruz Biotech). β-Actin (1:1000, Cell signaling) was the loading control. The specific
immunoreactivity was demonstrated by enhanced chemiluminescence (the immunoblots were
developed using the Super Signal West Pico Chemiluminescent Substrate Kit, Pierce Chemical,
Rockford, IL, USA) using Gel Logic Imaging System 1500 (Kodak; Molecular imaging System Corestea
Health Inc., Rochester, NY, USA). Total protein was measured by the Bradford method, as described
elsewhere, using BSA as a standard. Each experiment was repeated three times.
4.7. Assay of Pyruvate Dehydrogenase Kinase (PDK) Activity
For the Preparation of mitochondria, liver mitochondria were isolated from cells exposed to
compounds and prepared as described in [39]. Protein amount was assayed by Bradford method.
For the assessment of PDK, mitochondria were incubated for 25 min in KCl medium (120 mM KCl,
20 mM Tris-hydrochloride, pH 7.4, 5 mM K2HPO4, 2 mM EGTA) containing 10 µM of uncoupler
carbonyl cyanide-chlorophenylhydrazone to convert inactive PDH complex into active.
For the enzyme assay, PDK activity in mitochondrial extracts was measured according to
Wu et al. [39]. For the assay, mitochondrial pellets were disrupted in extraction buffer (50 mM
K2HPO4, 10 mM EGTA, 2 mM DTT, 1% BSA, 0.5% Triton-X100). PDK activity was expressed as the
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rate of ATP-dependent inactivation of the PDH complex and calculated as the apparent first-order
rate constant.
4.8. Glucose Consumption and Lactate Production Analysis
HTB-34 cells were seeded into multi-well plates and exposed to compounds for 24 h, as described
above, and then culture media were collected. Glucose concentration in media was determined
using a colorimetric test (Sigma-Aldrich) and lactate release from cells was determined in media
using commercially available kit (Sigma-Aldrich). Both assays were performed according to the
manufacturers protocols using Universal Microplate Reader ELX800NB (Bio-Tek Instruments INC,
Vinooski, VT, USA) and for both tests, the absorbance was measured at 540 nm.
4.9. Measurement of Mitochondrial ROS Level
Mitochondrial ROS were measured using MitoSox Red reagent (Invitrogen, Carlsbad, CA,
USA) according to manufacturer protocol using FACSCanto10C flow cytometer (BD Biosciences).
MitoSox superoxide indicator has excitation/emission maxima of 510 and 580 nm, respectively.
The fluorescence was also observed and recorded by fluorescence microscopy.
4.10. Quantitation of Unsaturated Fatty Acids
The extraction of total lipids from cells exposed to compounds was performed using
commercially available Lipid Extraction Kit (Cell Biolabs Inc., San Diego, CA, USA) according to
the manufacturer protocol.
The content of unsaturated fatty acids in cells was performed using commercially available kit
(Cell Biolabs Inc.) according to the manufacturer protocol.
The absorbance was measured at 550 nm using Bio-Tek microplate reader.
4.11. Statistical Analysis
The experimental data were shown as mean ± SD. Analysis was performed using one-way
ANOVA followed by a Duncan post-hoc test. p-values < 0.05 were considered statistically significant.
Calculations were carried out using the commercially available package, Statistica PL v.10 (StatSoft,
Tulusa, OK, USA).
5. Conclusions
In conclusion CA modestly activates AMPK, while Met exerts its effect on FA biosynthesis by
downregulation of several enzymes involved in the de novo synthesis of long unsaturated FA, such as
ACLY, FAS, ELOVL6, and SCD1. CA and Met induce cell death in human cervical metastatic cells by
two independent mechanisms, CA by increasing ROS production and Met by suppressing of substrate
formation for FA biosynthesis. The treatment of neoplastic cells with both compounds provides a
promising approach to evoke metastatic cervical HTB-34 cells death.
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ACC1 Acetyl-CoA Carboxylase 1
ACL ATP Citrate Lyase
FAS Fatty Acid Synthase
SCD1 Stearoyl-CoA Desaturase-1
ELOVL6 Fatty Acyl-CoA Elongase 6
AMPK 5′-Adenosine monophosphate-activated protein kinase
GLUT1 Glucose Transporter 1
PFK2 Phosphofructokinase 2
PDH Pyruvate Dehydrogenase Complex
PDK Pyruvate Dehydrogenase Kinase
GLS Glutaminase
ETC Electron Transport Chain
ROS Reactive Oxygen Species
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